Latest news with #Church&Dwight
USA Today
4 days ago
- Health
- USA Today
Fungi concerns prompt recall for certain Orajel, Zicam products
Fungi concerns prompt recall for certain Orajel, Zicam products Church & Dwight said this recall is limited exclusively to certain Zicam and Orajel swab products. Show Caption Hide Caption How to brush your teeth better You can get cleaner teeth with this brushing routine. ProblemSolved, USA TODAY The manufacturer of Orajel teething swabs and Zicam cold relief products has voluntarily issued a nationwide recall due to possible fungal contamination, according to a notice posted by the Food and Drug Administration (FDA). Church & Dwight Co., Inc. announced the recall on Friday, June 6, for certain Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs and Orajel Baby Teething Swabs. The affected products, which were distributed nationwide in the U.S. and Puerto Rico, may contain microbial contamination, identified as fungi, in the cotton swab components. Swabs containing fungi can potentially present "significant risk to the health and safety of consumers," including serious and life-threatening blood infections in consumers whose nasal cavity's mucous membrane lining may be compromised due to inflammation and mechanical injuries, according to the FDA recall notice. The health risks of using the recalled products are highest, and potentially severe or life-threatening, among children and people with compromised immune systems or other underlying medical conditions, according to the notice. What are the recalled Church & Dwight products? According to Church & Dwight, the recalled products include: Zicam Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product that was discontinued in December 2024. A nasal cleansing swab product that was discontinued in December 2024. Orajel Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What should consumers do? Individuals who have bought any of the recalled Church & Dwight products should stop using them immediately, according to the consumer goods company. Consumers can visit or call its consumer relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its consumer relations team Monday through Friday, 9 a.m. – 5 p.m. ET. Adverse reactions or quality problems experienced while using the recalled products can be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail or by fax. Individuals can complete and submit the report online. According to Church & Dwight, this recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall.
Yahoo
6 days ago
- Health
- Yahoo
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
Miami Herald
6 days ago
- Health
- Miami Herald
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination What can contaminated swabs do? Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' Exactly which Orajel and Zicam swabs are recalled? ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. What should you do now? If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
Yahoo
07-06-2025
- Business
- Yahoo
Church & Dwight (NYSE:CHD) Recalls Zicam and Orajel Products Over Microbial Contamination Concerns
Church & Dwight recently announced a voluntary recall of several products, including Zicam Cold Remedy Nasal Swabs and Orajel Baby Teething Swabs, due to potential fungal contamination risk, notably posing health threats to children and people with compromised immune systems. While no adverse events have been reported, this recall coincided with a 7.7% rise in the company's stock over the last month, reflecting broader market movements. The broader market rose by 1.8% over the past seven days and 13% over the last year, suggesting the recall might have temporarily added counterweight against the positive market trend. We've discovered 1 weakness for Church & Dwight that you should be aware of before investing here. Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. The voluntary recall of Church & Dwight's products, such as Zicam Cold Remedy Nasal Swabs, highlights challenges the company may face in its efforts to optimize its brand portfolio and stabilize earnings. This event, coupled with the company's rise in share price, mirrors broader market trends despite the recall's potential temporary impact. Over the past five years, the company's total shareholder return, including both share price growth and dividends, was 43.63%, showing a commendable performance in a challenging market environment. For context, during the past year, Church & Dwight's performance lagged behind not only the US Household Products industry, which experienced a 3.8% decline, but also the wider US market, which climbed 11%. Looking ahead, potential impacts on revenue and earnings forecasts from the recall include the continuation of U.S. sales declines or a slower recovery in earnings growth projections. Analysts anticipate a 2.7% annual revenue growth over the next three years, potentially hindered by ongoing consumer demand issues and macroeconomic pressures. Despite the recent share price movement and recall news, the company's current share price of US$92.07 trades at a small discount to analysts' consensus price target of US$99.6. This indicates expectations of moderate upside potential. Prospective investors might weigh these dynamics against the ongoing brand optimization and potential tariff impacts as Church & Dwight seeks to enhance its market position and financial health. Understand Church & Dwight's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:CHD. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
RBC upgrades Church & Dwight given conservative guidance and Touchland deal
-- RBC Capital Markets upgraded Church & Dwight (NYSE:CHD) to Outperform from Sector Perform and raised its price target to $114 from $100, saying recent underperformance creates an attractive entry point and expressing renewed confidence following meetings with management. The stock is down 6.3% year-to-date and has lagged the consumer staples ETF by over 10 percentage points. RBC said the recent pullback, driven by soft first-quarter results and macro concerns, has likely run its course. Church & Dwight's guidance adequately reflects the current challenges, including destocking, slower category growth, and tariff impacts, according to analysts. The firm added that recent consumption trends have stabilized, with scanner data showing modest gains in recent weeks. CHD expects U.S. sales, which account for about 80% of revenue, to decline slightly in 2024, with a modest recovery in the second half. Gross tariff exposure was pegged at $190 million, though the net impact is expected to be lower due to easing tariff rates and internal efficiencies. RBC also expressed optimism about the company's acquisition of Touchland, a fast-growing hand sanitizer brand. The $130 million business is expected to deliver double-digit growth and become accretive to earnings by 2026. Touchland, which has gained popularity among younger consumers, is seen as a strategic fit alongside recent successful acquisitions like Hero and TheraBreath. RBC expects its distribution through premium channels like Sephora and Amazon (NASDAQ:AMZN) to drive further growth. The firm also noted that Church & Dwight gained market share in 9 of its 14 major brands in Q1, with volume growth across 80% of the portfolio, a rare feat in the current environment. RBC raised its 2025-26 earnings estimate and said CHD's operating margin outlook is now tracking toward the upper end of its long-term target. Related articles RBC upgrades Church & Dwight given conservative guidance and Touchland deal Western Union growth constrained due to U.S. immigration policy: Oppenheimer Jefferies upgrades Rollins on sales hiring surge, sees growth ahead
